Evidence map›Paper›PMID 19110202›Full record

ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2009

Metabotropic glutamate receptors as targets for multipotential treatment of neurological disorders.

Kimberly R Byrnes, David J Loane, Alan I Faden

Open access · greenAbstract readReview
In one paragraph

Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 117 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Neuropathic pain; what we know and what we should do about it.Frontiers in pain research (Lausanne, Switzerland) · 2023
    Review
  11. Review
  12. Review
  13. Molecules (Basel, Switzerland) · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Kimberly R ByrnesDepartment of Neuroscience, Georgetown University Medical Center, Washington, DC 20057, USA. krb27@georgetown.edu
David J Loane
Alan I Faden
Georgetown University Medical Center · USGeorgetown University · US

Funding

Role of Cell Cycle Pathways in Traumatic Brain Injury (TBI)R01NS052568 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI FADEN, ALAN IRA · 2006 to 2016
$3.8M
Cell Cycle Pathways and Spinal Cord InjuryR01NS054221 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI FADEN, ALAN IRA · 2007 to 2011
$1.5M
NINDS NIH HHS 5R01NS054221-02NINDS NIH HHS R015R01NS052568-03NINDS NIH HHS R01 NS052568NINDS NIH HHS R01 NS054221
6 · The paper itself

Abstract

Glutamate is a major excitatory neurotransmitter in the CNS that is involved in numerous cellular functions, including cell death and survival. Metabotropic glutamate receptors (mGluR) are G-protein coupled receptors that have been classified into three groups on the basis of signal transduction pathways and pharmacological profiles. Group I, II, and III mGluRs are found on cell types within and peripheral to the CNS, including neurons, microglia, astrocytes, oligodendrocytes, T- and B-cell lymphocytes, osteoblasts, hepatocytes, and endothelial cells, among others. These receptors have a number of effects on cells that can influence outcome after trauma, including reducing neuronal and oligodendroglial cell death, inflammation, and endothelial permeability. Thus, mGluRs are a promising multipotential therapeutic approach. Because the pathology of CNS trauma and neurodegeneration is multifactorial (including, for example, oxidative stress, mitochondrial breakdown, and inflammation), therapies that serve to modulate multiple pathophysiological pathways may prove more effective than those directed at a single target. This review examines the multipotential therapeutic utility of mGluR modulation in acute and chronic injury and neurodegeneration.

Indexed as

AnimalsAstrocytesBrain InjuriesCentral Nervous SystemExcitatory Amino Acid AgonistsExcitatory Amino Acid AntagonistsHumansMicrogliaNeurodegenerative DiseasesNeuronsNeuroprotective AgentsReceptors, Metabotropic GlutamateSpinal Cord InjuriesExcitatory Amino Acid AgonistsExcitatory Amino Acid AntagonistsNeuroprotective AgentsReceptors, Metabotropic Glutamate

Identifiers

PMID19110202
PMCPMC2634659
OpenAlexW2158879871

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.